Status:
UNKNOWN
The Role of CYP2C19 on the Eradication of H. Pylori Infection:Implication of PK/PD Relationships
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Peptic Ulcer With H. Pylori Infection
Gastritis With H. Pylori Infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The objective of this trial is to find the rationale and the optimal dose and duration of regimen for the eradication of H. pylori infection using different proton pump inhibitors.
Detailed Description
Helicobacter pylori in known to be closely associated with the pathogenesis of gastroduodenal disorders such as peptide ulcer. Eradication of this bacterium is important in the treatment of these dise...
Eligibility Criteria
Inclusion
- Male and female dyspeptic patients with H. pylori-positive peptic ulcer or gastritis will be recruited at the university hospital in this study.
Exclusion
- 1)Pregnant or lactating female;\*2)Patients have endoscopy-based evidence of gastric malignancy, pyloric obstruction, and esophageal stricture requiring dilation, fresh clot, active bleeding, or perforated ulcers;3)Patients requiring anticoagulants or corticosteroid therapy (at dosages greater than the equivalent of prednisone, 10 mg/day);4)Patients with significant impairment of renal function (creatinine\>2mg/dl); liver function impairment (AST and ALT 2x upper limit of normal); severe cardiac disease, e.g. angina pectoris, myocardial infarction, cardiac arrhythmia, congestive heart failure (New York Heart Association Functional Classification III and IV) or acute respiratory disease;5)Patients with a history of esophageal and/or gastric varices;6)Use of other investigational drugs within 30 days prior to the study.
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
End Date :
April 1 2005
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00162877
Start Date
June 1 2004
End Date
April 1 2005
Last Update
November 23 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Internal Medicine, National Taiwan University Hospital
Taipei, Taiwan, 100